A Phase 1 interventional study of LY2963016 and US Approved Lantus in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®. The study will have 4 periods. In each period, a single injection will be administered before undergoing a euglycemic clamp that lasts for 24 hours. There will be at least a 7 day washout between each period. Side effects will be documented. Study participation is expected to last up to 14 weeks.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
Drug: LY2963016
Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
Drug: US Approved Lantus
Administered subcutaneously
Administered subcutaneously
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus
The AUC from time 0 to 24 hours (AUC0-24) of LY2963016 and US-Approved Lantus was measured.
Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus
Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods
Maximum Glucose Infusion Rate (Rmax)
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 45 | 46 |
| Received at least 1 dose of study drug | 45 | 46 |
| Completed | 45 | 46 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 45 | 46 |
| Completed | 44 | 44 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 44 | 44 |
| Completed | 44 | 44 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 44 | 44 |
| Completed | 41 | 42 |
| Not completed | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 2 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 41 | 42 |
| Completed | 41 | 42 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 41 | 42 |
| Completed | 40 | 42 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 40 | 42 |
| Completed | 40 | 42 |
| Not completed | 0 | 0 |
The AUC from time 0 to 24 hours (AUC0-24) of LY2963016 and US-Approved Lantus was measured.
| picomoles*hour/liter (pmol*h/L) | LY2963016 | US-approved Lantus |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus | 1720 ± 42 | 1900 ± 35 |
| picomoles/liter (pmol/L) | LY2963016 | US-approved Lantus |
|---|---|---|
| Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus | 103 ± 41 | 111 ± 34 |
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
| milligrams/kilograms/minute (mg/kg/min) | LY2963016 | US-approved Lantus |
|---|---|---|
| Maximum Glucose Infusion Rate (Rmax) | 2.12 ± 54 | 2.27 ± 58 |
Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
| milligrams/kilogram (mg/kg) | LY2963016 | US-approved Lantus |
|---|---|---|
| Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure | 1670 ± 60 | 1820 ± 74 |
Collected over Randomization to study completion. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 | — | 0/89 (0%) | 42/89 (47.2%) |
| US-approved Lantus | — | 0/90 (0%) | 42/90 (46.7%) |
| Event | LY2963016 | US-approved Lantus |
|---|---|---|
| Catheter site haematomaGeneral disorders | 10/89 | 9/90 |
| Catheter site swellingGeneral disorders | 9/89 | 7/90 |
| HeadacheNervous system disorders | 3/89 | 8/90 |
| Catheter site painGeneral disorders | 5/89 | 6/90 |
| Infusion site swellingGeneral disorders | 2/89 | 5/90 |
| Infusion site painGeneral disorders | 4/89 | 4/90 |
| PyrexiaGeneral disorders | 4/89 | 1/90 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/89 | 3/90 |
| Procedural site reactionInjury, poisoning and procedural complications | 2/89 | 4/90 |
All randomized participants
| Age, Continuous(years) | LY2963016 and US-approved Lantus |
|---|---|
| Mean | 32.7 ± 9.0 |
| Sex: Female, Male(Participants) | LY2963016 and US-approved Lantus |
|---|---|
| Female | 6 |
| Male | 85 |
| Race/Ethnicity, Customized(participants) | LY2963016 and US-approved Lantus |
|---|---|
| Asian | 90 |
| White | 1 |
| Region of Enrollment(participants) | LY2963016 and US-approved Lantus |
|---|---|
| Singapore | 91 |
The record gives a start of Sep 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine